Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. - Vincent,J-L.; Bernard,G.R.; Beale,R.; Doig,C.; Putensen,C.; Dhainaut,J-F. (Critical Care Medicine, 2005)